Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2018 1
2019 4
2021 1
2022 2
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

9 results

Results by year

Filters applied: . Clear all
Page 1
Eganelisib, a First-in-Class PI3Kγ Inhibitor, in Patients with Advanced Solid Tumors: Results of the Phase 1/1b MARIO-1 Trial.
Hong DS, Postow M, Chmielowski B, Sullivan R, Patnaik A, Cohen EEW, Shapiro G, Steuer C, Gutierrez M, Yeckes-Rodin H, Ilaria R, O'Connell B, Peng J, Peng G, Zizlsperger N, Tolcher A, Wolchok JD. Hong DS, et al. Clin Cancer Res. 2023 Jun 13;29(12):2210-2219. doi: 10.1158/1078-0432.CCR-22-3313. Clin Cancer Res. 2023. PMID: 37000164 Free PMC article. Clinical Trial.
Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
Taylor MH, Betts CB, Maloney L, Nadler E, Algazi A, Guarino MJ, Nemunaitis J, Jimeno A, Patel P, Munugalavadla V, Tao L, Adkins D, Goldschmidt JH, Cohen EEW, Coussens LM. Taylor MH, et al. Clin Cancer Res. 2022 Mar 1;28(5):903-914. doi: 10.1158/1078-0432.CCR-21-2547. Clin Cancer Res. 2022. PMID: 34862248 Free PMC article. Clinical Trial.
PI3Kγ inhibition suppresses microglia/TAM accumulation in glioblastoma microenvironment to promote exceptional temozolomide response.
Li J, Kaneda MM, Ma J, Li M, Shepard RM, Patel K, Koga T, Sarver A, Furnari F, Xu B, Dhawan S, Ning J, Zhu H, Wu A, You G, Jiang T, Venteicher AS, Rich JN, Glass CK, Varner JA, Chen CC. Li J, et al. Proc Natl Acad Sci U S A. 2021 Apr 20;118(16):e2009290118. doi: 10.1073/pnas.2009290118. Proc Natl Acad Sci U S A. 2021. PMID: 33846242 Free PMC article.
MST1R kinase accelerates pancreatic cancer progression via effects on both epithelial cells and macrophages.
Babicky ML, Harper MM, Chakedis J, Cazes A, Mose ES, Jaquish DV, French RP, Childers B, Alakus H, Schmid MC, Foubert P, Miyamoto J, Holman PJ, Walterscheid ZJ, Tang CM, Varki N, Sicklick JK, Messer K, Varner JA, Waltz SE, Lowy AM. Babicky ML, et al. Oncogene. 2019 Jul;38(28):5599-5611. doi: 10.1038/s41388-019-0811-9. Epub 2019 Apr 9. Oncogene. 2019. PMID: 30967626 Free PMC article.
Targeting Tumor-Associated Macrophages in Cancer.
Pathria P, Louis TL, Varner JA. Pathria P, et al. Trends Immunol. 2019 Apr;40(4):310-327. doi: 10.1016/j.it.2019.02.003. Epub 2019 Mar 17. Trends Immunol. 2019. PMID: 30890304 Review.
Integrin CD11b activation drives anti-tumor innate immunity.
Schmid MC, Khan SQ, Kaneda MM, Pathria P, Shepard R, Louis TL, Anand S, Woo G, Leem C, Faridi MH, Geraghty T, Rajagopalan A, Gupta S, Ahmed M, Vazquez-Padron RI, Cheresh DA, Gupta V, Varner JA. Schmid MC, et al. Nat Commun. 2018 Dec 19;9(1):5379. doi: 10.1038/s41467-018-07387-4. Nat Commun. 2018. PMID: 30568188 Free PMC article.